RNA signals and shunt response
A study in Brain identified candidate CSF RNA markers associated with improvement after shunt surgery.
Read the paper
Neurodegenerative diseases
Clearer decisions
before shunt surgery.
Adelle Diagnostics is developing molecular tests for neurodegenerative diseases and related conditions. ShuntIQ, our first test candidate, is designed to help clinicians assess who may benefit from shunt surgery for normal pressure hydrocephalus (NPH).
ShuntIQ is in development
01 Clinical focus
Treatable condition.
Uncertain outcome.
In normal pressure hydrocephalus, cerebrospinal fluid builds up in the brain. This can affect walking, thinking and bladder control. Surgery to drain the excess fluid with a shunt can help, but the benefit varies from patient to patient.
Understand NPHThe question behind ShuntIQ
Who is likely to benefit from a shunt?
We’re developing ShuntIQ to give care teams another piece of evidence before making that decision with patients.
02 The platform
From molecular patterns to evidence clinicians can use.
DIMA™ is Adelle’s biomarker discovery platform. It brings molecular profiling and machine learning together to look for signals linked to treatment response.
First application: ShuntIQ- 01
Profile the sample
Study molecular features in cerebrospinal fluid (CSF), including RNA and metabolites.
- 02
Find patterns linked to recovery
Use machine learning to identify candidate biomarkers associated with outcomes after surgery.
- 03
Develop and validate a test
ShuntIQ is a CSF test candidate designed to help assess likely shunt benefit. It is not available for clinical use.
03 Research & evidence
Follow the science.
See the research behind the approach and what the findings can tell us so far.
Metabolites and neurological recovery
Early research found associations between preoperative CSF metabolite patterns and recovery after shunting. The work has yet to be peer reviewed.
Read the preprintFrom Brown University research
Adelle grew out of a collaboration across neuroscience, neurosurgery and data science at Brown University.
See the Carney projectThese studies describe exploratory biomarker findings. They do not establish ShuntIQ’s clinical performance.
04 Team & advisors
Meet the Adelle team.
Our team brings together molecular biology, neuroscience, machine learning, neurosurgery and entrepreneurship.
-
Maria Grazia RuoccoPhD, MBA
CEO & Co-founder
A molecular scientist trained in genetics and microbiology, Maria helped lead the research that gave rise to Adelle.
RI Bio interview -
Alexander FleischmannPhD
Scientific Advisor
A Brown University neuroscientist whose lab studies the neural circuits that shape perception and behavior.
Brown profile -
Thomas SerrePhD
Technology and Innovation Advisor
A Brown University computational neuroscientist who uses machine learning to study visual perception.
Brown profile -
Petra KlingeMD, PhD
Medical Advisor
A Brown University professor of neurosurgery with clinical expertise in hydrocephalus and cerebrospinal fluid disorders.
Brown profile -
Danny Warshay
Business Advisor
An entrepreneur and executive director of Brown University’s Nelson Center for Entrepreneurship.
Brown profile
Our story
Inside Adelle.
Two short films tell the story of our first test candidate and the woman who inspired our name.
2:00
Illustrated concept film
Meet the ShuntIQ concept
Why the decision before surgery matters.
1:11
Illustrated brand story
The woman behind the name
Meet the medieval figure who inspired Adelle.
Films by Khodiyara AI. The scenes are illustrated.
05 Partner with us
Help bring better evidence to the shunt decision.
We welcome conversations with clinical researchers, neurology and neurosurgery teams, and partners in diagnostic development.